New York, NY -- (SBWIRE) -- 01/08/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: China Ming Yang Wind Power Group Ltd (NYSE:MY), VIVUS, Inc (NASDAQ:VVUS), Neuralstem, Inc (NYSEMKT:CUR), BioScrip Inc (NASDAQ:BIOS)
China Ming Yang Wind Power Group Ltd (NYSE:MY) showed a volume of 1.28 million shares by the end of last trade whereas the average volume of the stock remained 903,249.00 shares. The stock opened the session at $2.75 but then moved to $2.67. At that price, the stock showed a positive performance of 0.38%. China Ming Yang Wind Power Group Limited is a wind turbine manufacturer in China, focusing on designing, manufacturing, selling and servicing megawatt-class wind turbines. The Company’s products consist of basic models of wind turbines, each with a rated power capacity of 1.5 megawatt (MW); wind turbines with a rated power capacity of 2.0MW, and 2.5/3.0MW SCD wind turbines. Each product type may be installed with one of three rotor blade models depending on the location and wind conditions.
Will MY Continue To Move Higher? Find Out Here
VIVUS, Inc (NASDAQ:VVUS) opened the session at $9.32 and closed the session at $0.276. The stock showed a negative performance of -0.75% in previous trading session. VIVUS, Inc. is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. Its drug, Qsymia (phentermine and topiramate extended-release) was approved by the the United States Food and Drug Administration (FDA) for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese),
Has VVUS Found The Bottom And Ready To Gain Momentum? Find Out Here
Neuralstem, Inc (NYSEMKT:CUR) opened the session at $3.30 and closed the session at $3.35. The stock showed a positive performance of 4.04% in previous trading session. The beta of the stock remained 1.64. Neuralstem, Inc. is a development-stage company focused on the development and commercialization of treatments for central nervous system disease based on transplanting human neural stems cells and the use of small molecule drugs. The Company has developed and maintains a portfolio of patents and patent applications that form base for its research and development efforts in the area of neural stem cell research. The Company's focus is the development of methods to generate replacement cells from neural stem cells.
Why Should Investors Buy CUR After The Recent Gain? Just Go Here and Find Out
BioScrip Inc (NASDAQ:BIOS) the stock advanced 1.14% and finished the session at $7.11. Traded with volume of 1.25 million shares in the prior session and the average volume of the stock remained 1.44 million shares. The beta of the stock remained 1.45. BioScrip, Inc. (BioScrip) is a provider of pharmacy and home health services, which partners with patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and the delivery of prescription medications and home health services. Its platform provides service capabilities and the ability to deliver clinical management services, which offers patients a community-based and home-based care environment. Its core services are provided in coordination with,
Will BIOS Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)